While FDA Streamlines Biosimilar Approvals, Patents And Reimbursement Impede Access
FDA Commissioner Makary wants to expedite biosimilar approvals. But in the U.S., the greater impediments to access have been patent disputes and payment hurdles.
(Forbes, 2025-11-03T12:45:14Z)